Andersen Tawil Syndrome Treatment Market

Andersen Tawil Syndrome Treatment Market Snapshot (2023 to 2033)

The global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of USD 1.9 Billion in 2023 and is projected to reach USD 4.2 Billion by 2033, with a CAGR of 8.26%

An increase in the prevalence of Andersen-tawil syndrome is expected to drive the growth of the market. The increasing focus of the government to prioritize drugs for the treatment of rare diseases may also propel the growth of the Andersen-Tawil syndrome market during the forecast period. The increasing participation of organizations to support the treatment and to create awareness is also expected to drive the growth of the market. The rising Research and Development investments by the key players in the Andersen-Tawil Syndrome Market are also expected to boost the growth of the market.

However, the lack of large clinical studies may restrict the growth of the Andersen-Tawil syndrome market. The shortage of healthcare expected in the Middle East & Africa and Latin America may restrain the growth of the Andersen-Tawil Syndrome market in this region. The drug acetazolamide is likely to help with muscle weakness attacks, as well as dichlorphenamide (brand name KEVEYIS, the only FDA-approved periodic paralysis treatment).

Report Attribute	Details
Expected Market Value (2023)	USD 1.9 Billion
Anticipated Forecast Value (2033)	USD 4.2 Billion
Projected Growth Rate (2023 to 2033)	CAGR 8.26%

2018 to 2022 Andersen Tawil Syndrome Treatment Demand Analysis vs. Forecast 2023 to 2033

The market for Andersen Tawil Syndrome Treatment was worth USD 1.4 Billion in 2018 while growing at a CAGR of 6.3%. The increasing focus of the government to prioritize drugs for the treatment of rare diseases and growing participation from various organizations to treat this disease has been pushing healthcare industries and manufacturers to come up with next-generation drugs like ‘Acetazolamide’ for treatment of Andersen Tawil syndrome.

These developments have provided a boost for this market. Considering these factors, demand for this market is projected to grow at a CAGR of 8.26%, reaching a valuation of USD 4.2 Billion.

Which are Some Prominent Drivers of the Andersen Tawil Syndrome Treatment Market?

Mounting Research and development activities will propel the market expansion

Rising government funding for diagnostic procedures is likely to offer attractive opportunities for the Andersen-Tawil Syndrome diagnostic and treatment market which will lead to growth in product demand. The rising prevalence of disease, growing government initiatives, advancement in treatment options, genetic counseling, and increasing awareness of rare diseases are the factors that will expand the global Andersen disease treatment market.

Expanding Research and Development activities and the growing focus of major pharmaceutical companies toward novel treatment therapies will provide beneficial opportunities for the global Andersen disease treatment market in the forecast period of 2023 to 2033.

Moreover, the adoption of some of the more prominent diagnostic and treatment options including potassium supplements, molecular genetic testing, voluntary muscle contraction exercises, Holter monitoring, and electrocardiograms are anticipated to fuel market expansion.

What are the Challenges Projected to be Faced by the Market?

The high cost of treatment, slow growth in the adoption of novel drugs, and lack of awareness are the factors that will hamper the Andersen Tawil Syndrome Treatment market. Moreover, the availability of generic drugs is also expected to restrict market expansion.

Region-Wise Insights

North America dominates the market for Andersen Tawil Syndrome Treatment

North America dominates the Andersen disease treatment market due to the presence of major key players, advancement in treatment options, well-developed healthcare sector, rising prevalence of disease, and growing awareness towards health in this region.

Andersen Tawil Treatment market will witness great advancement in this region during the assessed time span. The improvement would be possible because of marketing examination instruments and because of existing players that are positively gotten comfortable with the market since the beginning.

Also, organization associations, associations, outcast chiefs, etc are channelizing their undertakings to make customer-driven things which will moreover add to the advancement in this locale. Increasing revenue, extended compensation, pattern setting advancement, and contraption, close by the tasks for spreading the thoughtfulness regarding the need will presumably make the Andersen Tawil therapeutics market grow tremendously.

South Asia to emerge as an Opportunistic Hub in Forthcoming Years

Andersen disease treatment market in South Asia is expected to grow during the forecast period due to the increasing research and development activities, increasing investment in the healthcare sector, emerging markets, and mounting government support.

South Asia is anticipated to experience the fastest growth in the Andersen-Tawil Syndrome market owing to improving healthcare infrastructure along with a rise in the number of cases suffering from the disease. In addition, increasing awareness may also help to fuel the growth of the Andersen-Tawil Syndrome market at a faster rate in this region. The developing private healthcare in countries like India is also expected to contribute to the growth of the Andersen-Tawil Syndrome market.

Category wise Insights

Type 1 Andersen Tawil Syndrome Treatment dominating the segment growth

Type 1 Andersen Tawil Syndrome Treatment dominates the segment by disease type with a market share of around 59% and a segment CAGR of 5.4%. The growth is attributed as highest in this segment because type 1 disease is caused by a known KCNJ2 gene mutation making it easier to identify and commence the treatment of the disease. North America is anticipated to dominate the industry for Type 1 disease treatment followed by Europe during the forecast period.

The hospital segment is expected to dominate the market by distribution channel

Hospital pharmacies accounted for 55% market share in 2022, followed by Online pharmacies. This segment is expected to retain its dominance by end of 2033 owing to well-developed health infrastructure, rising government initiatives, and growing investments in innovating drugs for the treatment of Andersen Tawil Syndrome Treatment is likely to augment this segment growth and fuel the industry’s demand.

Start-ups in Andersen Tawil Syndrome Treatment Market

• Founded in 2013, Lambda Health System is a developer of game-based robotic therapy for rehabilitation. The company is involved in the development of health systems that develops robotic equipment for assisted rehabilitation for people recovering from neurological injuries. It offers Lambda Robot, which is a rehabilitation device with 2 robotic arms. The arms have fixtures to hold the patient's legs and can adapt to a particular person. The company intends to make robotic rehabilitation a common theme in the treatment option for neural paraplegia. It has raised a total funding of USD 31.2 K from ‘Venture Kick’.
• Founded in 2008, Good Start Genetics is a molecular genetic information company based in Boston, US that offers carrier screening for inherited genetic diseases. The company provides genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders. The company is using next-generation sequencing (NGS) and other proven genetic screening technologies for their genetic tests. Good Start Genetics provides carrier screening for all disorders recommended by the American Congress of Obstetricians and Gynecologists & the American College of Medical Genetics. It has two products: GeneVu for carrier testing and EmbryVu for embryo screening. Customers can order GeneVu through Amazon as well. It has raised funding of USD 32 million from CRG, Orbimed, Safeguard Scientifics, and 1 Other Investor.

Market Competition

Key players in the Andersen Tawil Syndrome Treatment Market are: Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., Advanz Pharmaceuticals, Novartis AG, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Viatris Inc, Pfizer Inc

Some recent developments in this market are:

• In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of a 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.
• In December 2016, Strongbridge Biopharma plc acquired USA commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of the agreement, Taro Pharmaceutical Industries Ltd is to receive an upfront payment of USD 8.5 Million and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of USA rights expands the company’s rare disease portfolio to include neuromuscular diseases.
• In August 2015, Taro Pharmaceutical Industries Ltd received approval from the FDA for Keveyis (dichlorphenamide), an oral carbonic anhydrase inhibitor for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic, periodic paralysis, and related variants. The FDA approval of Keveyis is the most awaited, new, effective treatment option for many years for patients suffering from periodic paralysis.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 1.9 Billion
Market Value in 2033	USD 4.2 Billion
Growth Rate	CAGR of 8.26 % from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Disease Type, Drug Type, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa
Key Countries Profiled	USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Teva Pharmaceuticals Ltd; Zydus Pharmaceuticals, Inc.; Sun Pharmaceuticals Industries Ltd.; Advanz Pharmaceuticals; Novartis AG; Mylan N.V; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd.; Viatris Inc.; Pfizer Inc.
Customization	Available Upon Request

Key Segments Profiled in the Andersen Tawil Syndrome Treatment Market Industry survey

Disease Type:

• Type 1
• Type 2

Drug Class:

• Carbonic Anhydrate Inhibitors
• Acetazolamide
• Dichloropenamide
• Antiarrhythmic Drugs
• Amiodarone
• Flecainide
• Beta-Blockers
• Atenolol

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the Forecasted Growth Rate for the Global Anderson Tawil Syndrome Treatment Market?

The global market is forecasted to develop at an impressive 8.26% CAGR until 2033.

Which is the Net Worth of the Global Market for Anderson Tawil Syndrome Treatment Services?

The total demand in 2023 is estimated to generate a revenue of around USD 1.9 billion.

What is the Growth Trend in South Asia in Adoption of Anderson Tawil Syndrome Treatment Services?

Rising government spending on healthcare infrastructure is driving the regional market at a faster rate.

Which End User Segment Creates a Higher Demand for Anderson Tawil Syndrome Treatment?

Hospital Pharmacies segment generated almost 55% of the total revenue in 2022.

Which Type of Anderson Tawil Syndrome Treatment is the Largest Segment in the Global Market?

Type 1 Anderson Tawil Syndrome created nearly 59% of the global demand in 2022.